MarketInOut Stock Screener Log In | Sign Up
 

ImmunityBio Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/28/2026 12:59
ImmunityBio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization7,561.9 mln
Float394 mln
Earnings Date08/12/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

4.18
Highly suspicious

Relative Strength

26 / 100
Underperforming

Debt / Equity

-1.03
Negative equity

Dividend Yield

0.00%
No dividend

DPS

0.00
No dividend

Business Description

ImmunityBio is a San Diego-based biotech company working to fight cancer and infectious diseases by developing treatments that strengthen the body's own immune system. Its most notable product, Anktiva, has received FDA approval for use in certain bladder cancer patients who have not responded to standard therapy. The company works across several treatment approaches, including proteins, vaccines, and cell-based therapies, and collaborates with leading research organizations such as the National Cancer Institute and partners in India and China.

Key Fundamentals

EPS-0.85
RPS0.12
ROIC-115
ROA-83.28
EBITDA, mln-224
EV / EBITDA-12.50
EV / EBIT-12.23
Revenue, mln113
EV / Revenue64.40

Financial Strength

Altman Z-Score-6.27
Piotroski F-Score 3 / 9
Beneish M-Score4.18
Short Ratio9.31
Short % of Float35.56

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0% 27 / 100   
1 Month 15.66% 85 / 100   
2 Months -6.5% 24 / 100   
6 Months 274% 99 / 100   
1 Year 218% 96 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us